| abstract |
Provided is a pharmaceutical combination for treating or preventing ophthalmic diseases. Antagonist A, or a pharmaceutically acceptable salt thereof, a PDGF (platelet derived growth factor) antagonist, and aflibercept, KH902 VEGF receptor-Fc fusion protein, sFLT01, sFLT02, or a pharmaceutical thereof A pharmaceutical combination effective for treating or preventing ophthalmic diseases, comprising a VEGF (vascular endothelial growth factor) antagonist, which is an acceptable salt, and wherein a PDGF antagonist and a VEGF antagonist are administered sequentially or simultaneously. [Selection figure] None |